https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=35306963&retmode=xml&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=atg-naïve+patients&datetype=edat&usehistory=y&retmax=5&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&WebEnv=MCID_679579be8aed20622400e4a7&query_key=1&retmode=xml&retmax=5&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908 Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution. | LitMetric

Objective: To explore the efficacy and safety of thrombopoietin receptor agonists (TPO-RAs) without anti-thymocyte globulin (ATG) in ATG-naïve patients with aplastic anemia (AA) in a real-world setting.

Methods: We retrospectively evaluated treatment outcomes in 45 consecutive ATG-naïve patients with AA who received TPO-RAs between 2017 and 2021 at our hospital.

Results: ATG ineligibility was due to advanced age (≥ 70 years),  = 22; not recommended under Japanese guidelines due to mild symptoms,  = 13; patient preference,  = 6; uncontrolled heart failure,  = 2; uncontrolled diabetes mellitus,  = 2; chronic renal failure,  = 2; invasive aspergillosis,  = 1. Twenty-eight patients (62%) achieved hematologic response in at least unilineage after 6 months' treatment, while 38 (84% in unilineage response-eligible patients) and four (25% in trilineage response-eligible patients) patients achieved at least unilineage and trilineage responses, respectively, at any point during the follow-up period. Five patients switched from eltrombopag to romiplostim because of adverse events or lack of efficacy, and two developed hematologic malignancies. Eltrombopag was effective even in elderly ATG-ineligible patients with severe AA. The 2-year overall survival rate was 84.3%, with a median 26.3-month follow-up. Time from diagnosis to eltrombopag treatment initiation tended to affect the response ( = 0.0727), but no factors that significantly predicted hematologic response were identified.

Conclusions: We found eltrombopag to be effective even in elderly ATG-naïve patients with severe AA, indicating that TPO-RA treatment should be considered in patients ineligible for ATG treatment because of age, complications, or severe AA.

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2022.2045725DOI Listing

Publication Analysis

Top Keywords

atg-naïve patients
12
patients
11
thrombopoietin receptor
8
receptor agonists
8
patients aplastic
8
aplastic anemia
8
failure  = 2
8
hematologic response
8
response-eligible patients
8
eltrombopag effective
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!